Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...

Scribe Therapeutics is slimming down its workforce by 20% as it readies its cardiometabolic pipeline for the clinic, a ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...